MLE Inhibitors
Chemical inhibitors of MLE can interfere with the protein's function by targeting various signaling pathways and enzymes that are crucial for its activity. Bisindolylmaleimide I, for instance, selectively inhibits protein kinase C (PKC). Since PKC is involved in the activation of signaling pathways that MLE relies on for its function, its inhibition by Bisindolylmaleimide I can lead to reduced MLE activity. Similarly, Y-27632 targets the Rho-associated protein kinase (ROCK), potentially altering cytoskeletal dynamics which are essential for MLE's function if its activity requires cytoskeletal interaction. SB203580, by inhibiting p38 MAP kinase, could disrupt stress response signaling pathways, subsequently affecting MLE's function if it is involved in these pathways. LY294002 and Wortmannin, both inhibitors of phosphoinositide 3-kinases (PI3K), can hinder the PI3K/Akt signaling pathway, which may be necessary for MLE activity. PD98059 and U0126, which selectively inhibit MEK1/2, can prevent the activation of the ERK pathway, potentially leading to the inhibition of MLE function if it is dependent on this pathway for signal transduction.
Continuing with the inhibition mechanisms, SP600125 disrupts the function of c-Jun N-terminal kinase (JNK), which could lead to the inhibition of MLE's activity if JNK signaling is required. PP2, which selectively inhibits Src family tyrosine kinases, could alter cell adhesion and migration signaling pathways, affecting MLE function if it requires Src kinase signaling. Rapamycin, an inhibitor of mTOR, can disrupt cell growth and proliferation processes, which may affect MLE function if it is linked to mTOR signaling pathways. Gefitinib targets the epidermal growth factor receptor (EGFR) tyrosine kinase, which could lead to altered signaling that regulates MLE function. Lastly, Imatinib, by inhibiting tyrosine kinases like BCR-ABL, c-Kit, and PDGFR, could interfere with signaling pathways upon which MLE's function relies, subsequently inhibiting its activity. Each inhibitor, by targeting its specific kinase or pathway, can contribute to the overall reduction in MLE activity by disrupting the necessary signaling cascades that MLE requires to function effectively.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Bisindolylmaleimide I selectively inhibits protein kinase C (PKC), which is involved in the activation of certain signaling pathways that MLE may rely on for its function, leading to the inhibition of MLE’s activity as a result of impaired signaling. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a selective inhibitor of ROCK (Rho-associated protein kinase), which may be involved in cellular pathways that regulate the cytoskeleton and related mechanisms. Inhibition of ROCK could lead to alterations in cytoskeleton dynamics, which may inhibit MLE function if MLE requires cytoskeletal interactions for its activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. By inhibiting p38 MAP kinase, this compound may disrupt signaling pathways that regulate stress responses and inflammatory cytokines, potentially inhibiting MLE function if MLE is involved in these stress response pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, LY294002 can disrupt downstream signaling pathways like Akt signaling, which may inhibit MLE function if PI3K signaling is necessary for MLE activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 selectively inhibits MEK, which is part of the MAPK/ERK pathway. Inhibition of MEK leads to blockade of the ERK pathway, which can potentially inhibit MLE function if MLE depends on the MAPK/ERK pathway for signal transduction. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). By inhibiting JNK, it can disrupt JNK signaling pathways that may be necessary for MLE function, leading to the inhibition of MLE activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of MEK1 and MEK2. By inhibiting these kinases, U0126 can prevent the activation of the ERK pathway, which may inhibit MLE function if MLE is dependent on the ERK signaling pathway. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. Inhibition of Src kinases can alter various signaling pathways including those related to cell adhesion and migration, potentially inhibiting MLE activity if MLE requires Src kinase signaling for its function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K. By inhibiting PI3K, Wortmannin can disrupt important cell survival and growth pathways, potentially inhibiting MLE function if MLE is involved in PI3K/Akt signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR (mammalian target of rapamycin), which is a key regulator of cell growth and proliferation. Inhibition of mTOR may disrupt processes necessary for MLE function if MLE activity is linked to mTOR signaling pathways. | ||||||